The University of Massachusetts Amherst

2018 PEP Fellow, Elizabeth Evans, research on obstacles to treating opioid use disorder with medication featured in Medicine News Line

In an effort to find ways to improve long-term outcomes for people with opioid use disorder, 2018 PEP Fellow, Elizabeth Evans set out to study the obstacles to treating this chronic condition with an effective medication, buprenorphine-naloxone. “Very few people with opioid use disorder ever get treatment for it – 10 percent or less,” says Evans in a Medicine News Line story. “Of those who do, few remain in treatment long enough to really benefit from it.” In a newly published paper in the Journal of Substance Abuse Treatment, lead author Evans and colleagues identify factors that inhibit the long-term use of buprenorphine, which was approved in 2002 by the FDA to treat opioid use disorder. Story also featured in News Medical Life SciencesScience CodexBusiness WestHealio, MassLive, and Boston Globe.